Public trial registry of the CCC-Munich

Trial Xolair (Omalizumab)

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
Xolair (Omalizumab)
World
Full title
:

A PHASE III; Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the efficacy and safety of XOLAIR (Omalizumab) in Patients with chronic Idiopathic Urticaria (CIU) Who remain Symptomatic Despite Antihistamine Treatment (H1)

World
Responsible organization
:
Hautklinik MRI Ismanínger Str. 22 81675 München Germany
Indications
Classification Code Description
- - Other trials
ICD-10-GM L50.1 Idiopathische Urtikaria
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment active
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Zielgerichtet

Participants
Function Prename Surname Organization
World Responsible contact Knut Brockow Hautklinik MRI Ismanínger Str. 22 81675 München Germany Magnifier